Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 102Carcinoma, Non-Small-Cell Lung 84Glioblastoma 77Brain Neoplasms 75Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 51Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Melanoma 35Ovarian Neoplasms 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

nirogacestat 1luspatercept 1luprolide acetate gel depot 1exemestane 1etoposide phosphate 1darolutamide 1X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Leuprolide 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Magnetic Resonance Spectroscopy × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡